Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04FYL
|
|||
| Former ID |
DIB009998
|
|||
| Drug Name |
Contusugene ladenovec
|
|||
| Synonyms |
Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR
Click to Show/Hide
|
|||
| Indication | Oral cancer [ICD-11: 2B6E; ICD-10: C00-C14] | Phase 3 | [1] | |
| Liver metastasis [ICD-11: 2D80; ICD-10: C78.7] | Phase 1 | [2] | ||
| Company |
Introgen Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00041613) Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.